Preview

Евразийский кардиологический журнал

Расширенный поиск

АНТИКОАГУЛЯНТНАЯ ТЕРАПИЯ ПРИ ХРОНИЧЕСКОЙ БОЛЕЗНИ ПОЧЕК И ФИБРИЛЛЯЦИИ ПРЕДСЕРДИЙ: ОСЬ ВРАЩЕНИЯ МЕЖДУ ПОЛЮСАМИ РИСКА

Полный текст:

Аннотация

Частая коморбидность фибрилляции предсердий (ФП) и хронической болезни почек (ХБП) в общей популяции продемонстрирована во многих эпидемиологических исследованиях. Большинству пациентов c установленным диагнозом ФП рекомендована постоянная антикоагулянтная терапии (АКТ) с целью профилактики ишемического инсульта и тромбоэмболических осложнений (ТЭО). При дисфункции почек на всех стадиях ХБП наблюдаются изменения в системе гемостаза, связанные как с повышением протромбогенной активности, так и развитием коагулопатии, увеличивающей угрозу кровотечения. Поэтому у пациентов с ХБП и ФП важным аспектом АКТ является выбор оптимального антикоагулянта, обеспечивающего баланс между рисками инсульта и геморрагических осложнений, чему и посвящена данная статья.

Об авторах

Ж. Д. Кобалава
ФГАОУ ВО «Российский университет дружбы народов»
Россия

Д.м.н., профессор, заведующая кафедрой внутренних болезней с курсом кардиологии и функциональной диагностики

117198, г. Москва, ул. Миклухо-Маклая, д. 6

тел. 8(499)134-6591



А. А. Шаваров
ФГАОУ ВО «Российский университет дружбы народов»
Россия

К.м.н., доцент, доцент кафедры внутренних болезней с курсом кардиологии и функциональной диагностики

117198, г. Москва, ул. Миклухо-Маклая, д. 6.

тел. 8(499)135-9177



Список литературы

1. Banerjee A., Marin F., Lip G.Y. A new landscape for stroke prevention in atrial fibrillation: focus on new anticoagulants, antiarrhythmic drugs, and devices. Stroke, 2011; 42: 3316-22.

2. Marinigh R., Lane D.A., Lip G.Y. Severe renal impairment and stroke prevention in atrial fibrillation: implications for hromboprophylaxis and bleeding risk. J Am Coll Cardiol. 2011; 57: 1339-48.

3. Reinecke H., Brand E., Mesters R., et al. Dilemmas in the management of atrial fibrillation in chronic kidney disease. J Am Soc Nephrol. 2009; 20: 705-11.

4. Baber U., Howard V.J., Halperin J.L., et al. Association of chronic kidney disease with atrial fibrillation among adults in the United States: REasons for Geographic and Racial Differences in Stroke (REGARDS) Study. Circ Arrhythm Electrophysiol. 2011; 4: 26-32.

5. Soliman E.Z., Prineas R.J., Go A.S., et al.; Chronic Renal Insufficiency Cohort (CRIC) Study Group. Chronic Renal Insufficiency Cohort (CRIC) Study Group. Chronic kidney disease and prevalent atrial fibrillation: the Chronic Renal Insufficiency Cohort (CRIC). Am Heart J. 2010; 159: 1102-7.

6. Pavord S., Myers B. Bleeding and thrombotic complications of kidney disease. Blood Rev. 2011; 25: 271-8.

7. Falga C., Capdevila J.A., Soler S., et al; RIETE Investigators. Clinical outcome of patients with venous thromboembolism and renal insufficiency: findings from the RIETE registry. Thromb Haemost. 2007; 98: 771-6.

8. Bos M.J., Koudstaal p. J., Hofman A., Breteler M.M. Decreased glomerular filtration rate is a risk factor for hemorrhagic but not for ischemic stroke: the Rotterdam study. Stroke. 2007; 38: 3127-32.

9. Vazquez E., Sanchez-Perales C., Garcia-Cortes M.J., et al. Ought dialysis patients with atrial fibrillation be treated with oral anticoagulants? Int J Cardiol. 2003; 87: 135-9.

10. Clark N. Low-molecular-weight heparin use in the obese, elderly, and in renal insufficiency. Thromb Res. 2008; 123: 58-61.

11. Lim W. Low-molecular-weight heparin in patients with chronic renal insufficiency. Intern Emerg Med. 2008; 3: 319-23.

12. Schmid Р., Fischer A.G., Wuillemin W.A. Low-molecularweight heparin in patients with renal insufficiency. Swiss Med Wkly. 2009; 139: 438-52.

13. Hoffmann Р., Keller F. Increased major bleeding risk in patients with kidney dysfunction receiving enoxaparin: a meta-analysis. Eur J Clin Pharmacol. 2012; 68: 757-65.

14. U.S. Renal Data System (USRDS) 2006 Annual Data Report. Volume 2: Atlas of End-Stage Renal Disease in the United States. Bethesda, MD: National Institute of Diabetes and Digestive and Kidney Diseases, 2006.

15. Apostolakis S., Guo Y., Lane D.A., et al. Renal function and outcomes in anticoagulated patients with non-valvular atrial fibrillation: the AMADEUS trial. Eur Heart J. 2013; 34: 3572-9.

16. Stevens L.A., Coresh J., Greene T., Levey A.S. Assessing kidney function-measured and estimated glomerular filtration rate. N Engl J Med. 2006; 354: 2473-83.

17. Iguchi Y., Kimura K., Kobayashi K., et al. Relation of atrial fibrillation to glomerular filtration rate. Am J Cardiol. 2008; 102(8): 1056-9.

18. McManus D.D., Corteville D.C., Shlipak M.G., et al. Relation of kidney function and albuminuria with atrial fibrillation (from the Heart and Soul Study). Am J Cardiol. 2009; 104(11): 1551-5.

19. Asselbergs F.W., van den Berg M.p., Diercks G.F., et al. C-reactive protein and microalbuminuria are associated with atrial fibrillation. Int J Cardiol. 2005: 98(1): 73-7.

20. Watanabe H., Watanabe T., Sasaki S., et al. Close bidirectional relationship between chronic kidney disease and atrial fibrillation: the Niigata preventive medicine study. Am Heart J. 2009; 158(4): 629-36.

21. Alonso A., Lopez F.L., Matsushita K., et al. Chronic kidney disease is associated with the incidence of atrial fibrillation: the Atherosclerosis Risk in Communities (ARIC) study. Circulation. 2011; 123(25): 2946-53.

22. Atar I., Konas D., Acikel S., et al. Frequency of atrial fibrillation and factors related to its development in dialysis patients. Int J Cardiol. 2006; 106(1): 47-51.

23. Winkelmayer W.C., Patrick A.R., Liu J., et al. The increasing prevalence of atrial fibrillation among hemodialysis patients. J Am Soc Nephrol. 2011; 22(2): 349-57.

24. Go A.S., Chertow G.M., Fan D., et al. Chronic kidney disease and the risks of death, cardiovascular events, and hospitalization. N Engl J Med. 2004; 351: 1296-305.

25. Abbott K.C., Trespalacios F.C., Taylor A.J., Agodoa L.Y. Atrial fibrillation in chronic dialysis patients in the United States: Risk factors for hospitalization and mortality. BMC Nephrol. 2003; 4: 1-10.

26. Vazquez E., Sanchez-Perales C., Lozano C., et al. Comparison of prognostic value of atrial fibrillation versus sinus rhythm in patients on long-term hemodialysis. Am J Cardiol. 2003; 92: 868 -71.

27. Corrao S., Argano C., Nobili A., et al., REPOSI Investigators Brain and kidney, victims of atrial microembolism in elderly hospitalized patients? Data from the REPOSI study. Eur J Intern Med. 2015; 26: 243-9.

28. Go A.S., Hylek E.M., Phillips KA., et al. Prevalence of diagnosed atrial fibrillation in adults: national implications for rhythm management and stroke prevention: the AnTicoagulation and Risk Factors in Atrial Fibrillation (ATRIA) study. JAMA. 2001; 285: 2370-5.

29. Vazquez E., Sanchez-Perales C., Garcia-Garcia F., et al. Atrial fibrillation in incident dialysis patients. Kidney Int. 2009; 76: 324-30.

30. Schaeffner E.S., Ebert N., Delanaye p., et al. Two novel equations to estimate kidney function in persons aged 70 years or older. Ann Intern Med. 2012; 157: 471-81.

31. Levey A.S., de Jong p. E., Coresh J., et al. The definition, classification, and prognosis of chronic kidney disease: a KDIGO controversies conference report. Kidney Int. 2011; 80: 17-28.

32. Go A.S., Fang M.C., Udaltsova N., et al.; ATRIA Study Investigators. Impact of proteinuria and glomerular filtration rate on risk of thromboembolism in atrial fibrillation: the anticoagulation and risk factors in atrial fibrillation (ATRIA) study. Circulation. 2009; 119: 1363-9.

33. Bonde A.N., Lip G.Y., Kamper A.L., et al. Net clinical benefit of antithrombotic therapy in patients with atrial fibrillation and chronic kidney disease: a nationwide observational cohort study. J Am Coll Cardiol. 2014; 64: 2471-82.

34. Hart R.G., Pearce L.A., Aguilar M.I. Meta-analysis: antithrombotic therapy to prevent stroke in patients who have non-valvular atrial fibrillation. Ann Intern Med. 2007; 146(12): 857-67.

35. Nakagawa K., Hirai T., Takashima S., et al. Chronic kidney disease and CHADS(2) score independently predict cardiovascular events and mortality in patients with non-valvular atrial fibrillation. Am J Cardiol. 2011; 107(6): 912-6.

36. Gage B.F., Waterman A.D., Shannon W., et al. Validation of clinical classification schemes for predicting stroke: results from the National Registry of Atrial Fibrillation. JAMA. 2001; 285: 2864-70.

37. Wizemann V., Tong L., Satayathum S., et al. Atrial fibrillation in hemodialysis patients: clinical features and associations with anticoagulant therapy. Kidney Int. 2010; 77: 1098-106.

38. Genovesi S., Pogliani D., Faini A., et al. Prevalence of atrial fibrillation and associated factors in a population of long-term hemodialysis patients. Am J Kidney Dis. 2005; 46(5): 897-902.

39. Guo Y., Wang H., Zhao X., et al. Sequential changes in renal function and the risk of stroke and death in patients with atrial fibrillation. Int J Cardiol. 2013; 168: 4678-84.

40. Tsagalis G., Akrivos T., Alevizaki M., et al. Renal dysfunction in acute stroke: an independent predictor of long-term all combined vascular events and overall mortality. Nephrol Dial Transplant. 2009; 24: 194-200.

41. Kumai Y., Kamouchi M., Hata J., et al.; FSR Investigators. Proteinuria and clinical outcomes after ischemic stroke. Neurology. 2012; 78: 1909-15.

42. Yahalom G., Schwartz R., Schwammenthal Y., et al. Chronic kidney disease and clinical outcome in patients with acute stroke. Stroke. 2009; 40: 1296-303.

43. Dumaine R.L., Montalescot G., Steg p. G., et al. Renal function, atherothrombosis extent, and outcomes in high-risk patients. Am Heart J. 2009; 158(1): 141-8.e1.

44. Olesen J.B., Lip G.Y., Kamper A.L., et al. Stroke and bleeding in atrial fibrillation with chronic kidney disease. N Engl J Med. 2012; 367: 625-35.

45. Chan K.E., Lazarus J.M., Thadhani R., Hakim R.M. Warfarin use associates with increased risk for stroke in hemodialysis patients with atrial fibrillation. J Am Soc Nephrol. 2009; 20: 2223-33.

46. Sood M.M., Larkina M., Thumma J.R., et al. Major bleeding events and risk stratification of antithrombotic agents in hemodialysis: results from the DOPPS. Kidney Int. 2013; 84: 600-8.

47. Hart R.G., Pearce L.A., Asinger R.W., Herzog C.A. Warfarin in atrial fibrillation patients with moderate chronic kidney disease. Clin J Am Soc Nephrol. 2011; 6: 2599-604.

48. Lai H.M., Aronow W.S., Kalen p., et al. Incidence of thromboembolic stroke and of major bleeding in patients with atrial fibrillation and chronic kidney disease treated with and without warfarin. Int J Nephrol Renovasc Dis. 2009; 2: 33-7.

49. Limdi N.A., Beasley T.M., Baird M.F., et al. Kidney function influences warfarin responsiveness and hemorrhagic complications. J Am Soc Nephrol. 2009; 20: 912-21.

50. Genovesi S., Rossi E., Pogliani D., et al. The nephrologists anticoagu- lation treatment patterns/regimens in chronic hemodialysis patients with atrial fibrillation. J Nephrol. 2014; 27: 187-92.

51. Genovesi S., Rossi E., Gallieni M., et al. Warfarin use, mortality, bleeding, and stroke in haemodialysis patients with atrial fibrillation. Nephrol Dial Transplant. 2015; 30: 491-98.

52. Kapoor K.G., Bekaii-Saab T. Warfarin-induced allergic interstitial nephritis and leucocytoclastic vasculitis. Intern Med J. 2008; 38: 281-3.

53. Wysowski D.K., Nourjah p., Swartz L. Bleeding complications with warfarin use: a prevalent adverse effect resulting in regulatory action. Arch Intern Med. 2007; 167: 1414-19.

54. Brodsky S.V., Nadasdy T., Rovin B.H., et al. Warfarin-related nephropathy occurs in patients with and without chronic kidney disease and is associated with an increased mortality rate. Kidney Int. 2011; 80: 181-9.

55. Abt A.B., Carroll L.E., Mohler J.H. Thin basement membrane disease and acute renal failure secondary to gross hematuria and tubular necrosis. Am J Kidney Dis. 2000; 35: 533-6.

56. Kabir A., Nadasdy T., Nadasdy G., Hebert L.A. An unusual cause of gross hematuria and transient ARF in an SLE patient with warfarin coagulopathy. Am J Kidney Dis. 2004; 43: 757-60.

57. Spetie D.N., Nadasdy T., Nadasdy G., et al. Proposed pathogenesis of idiopathic loin pain-hematuria syndrome. Am J Kidney Dis. 2006; 47: 419-27.

58. Brodsky S.V., Satoskar A., Chen J., et al. Acute kidney injury during warfarin therapy associated with obstructive tubular red blood cell casts: a report of 9 cases. Am J Kidney Dis. 2009; 54: 1121-6.

59. Brodsky S.V., Collins M., Park E., et al. Warfarin therapy that results in an International Normalization Ratio above the therapeutic range is associated with accelerated progression of chronic kidney disease. Nephron Clin Pract. 2010; 115: c142-146.

60. Kaw D., Malhotra D. Platelet dysfunction and end-stage renal disease. Semin Dial. 2006; 19: 317-22.

61. Boccardo p., Remuzzi G., Galbusera M. Platelet dysfunction in renal failure. Semin Thromb Haemost. 2004; 30: 579-89.

62. Hylek E.M., Skates S.J., Sheehan M.A., Singer D.E. An analysis of the lowest effective intensity of prophylactic anticoagulation for patients with nonrheumatic atrial fibrillation. N Engl J Med. 1996; 335: 540-6.

63. Sardar Р., Chatterjee S., Herzog E., et al. Novel oral anticoagulants in patients with renal insufficiency: a metaanalysis of randomized trials. Can J Cardiol. 2014; 30: 888-97.

64. Lip G.Y.H., Clemens A., Noack H., et al. Patient outcomes using the European label for dabigatran A post-hoc analysis from the RE-LY database. Thromb Haemost. 2014; 111: 933-42. doi: 10.1160/TH13-09-0734.

65. Hijazi Z, Hohnloser S.H., Oldgren J., et al. Efficacy and safety of dabigatran compared with warfarin in relation to baseline renal function in patients with atrial fibrillation: a RE-LY trial analysis. Circulation. 2014; 129(9): 961-70. doi: 10.1161/CIRCULATIОNAHA.113.003628.

66. В hm M., Ezekowitz M.D., Connolly S., et al. Changes in renal function in patients with atrial fibrillation: an analysis from the RE-LY trial. JACC. 2015; 65(23): 2481-93.

67. Hernandez I., Zhang Y. Comparing stroke and bleeding with rivaroxaban and dabigatran in atrial fibrillation: analysis of the US Medicare part D data. Am J Cardiovasc Drugs. 2017; 17(1): 37-47. doi: 10.1007/S40256-016-0189-9.

68. Kirchhof P., Benussi S., Kotecha D., et al. 2016 ESC Guidelines for the management of atrial fibrillation developed in collaboration with EACTS. Europace. 2016; 18: 1609-78.

69. Beyth R.J., Quinn L.M., Landefeld C.S. Prospective evaluation of an index for predicting the risk of major bleeding in outpatients treated with warfarin. Am J Med. 1998; 105: 91-9.

70. Gage B.F., YanY., Milligan P.E., etal. Clinical classifications chemes for predicting haemorrhage: results from the National Registry of Atrial Fibrillation (NRAF). Am Heart J. 2006; 151: 713-9.

71. Pisters R., Lane D.A., Nieuwlaat R., et al. Anovel userfriendly score (HAS-BLED) to assess 1-year risk of major bleeding in atrial fibrillation patients: the Euro Heart Survey. Chest. 2010; 138: 1093-10.

72. Ahrens I., Lip G.Y., Peter K. New oral anticoagulant drugs in cardiovascular disease. Thromb Haemost. 2010; 104: 49-60.

73. Budnitz D.S., Lovegrove M.C., Shehab N., Richards C.L. Emergency hospitalizations for adverse drug events in older Americans. N Engl J Med. 2011 ; 365: 2002-12.

74. Granger C.B., Alexander J.H., McMurray J.J, et al. Apixaban versus warfarin in patients with atrial fibrillation. N Engl J Med. 2011; 365: 981-92.

75. Patel M.R., Mahaffey K.W., Garg J., et al.; ROCKET AF Investigators. Rivaroxaban versus warfarin in nonvalvular atrial fibrillation. N Engl J Med. 2011 ; 365: 883-91.

76. Eikelboom J.W., Wallentin L., Connolly S.J., et al. Risk of bleeding with 2 doses of dabigatran compared with warfarin in older and younger patients with atrial fibrillation: An analysis of the randomized evaluation of long-term anticoagulant therapy (RE-LY) trial. Circulation. 2011; 123: 2363-72.

77. Hemmelgarn B.R., Zhang J., Manns B.J., et al. Progression of kidney dysfunction in the community-dwelling elderly. Kidney Int. 2006; 69: 2155-61.

78. Mantha S., Ansell J. An indirect comparison of dabigatran, rivaroxaban and apixaban for atrial fibrillation. Thromb Haemost. 2012; 108(9): 476-84.

79. Lip G.Y., Larsen T.B., Skjoth F., Rasmussen L.H. Indirect comparisons of new oral anticoagulant drugs for efficacy and safety when used for stroke prevention in atrial fibrillation. J Am Coll Cardiol. 2012; 60(8): 738-46.

80. Hariharan S., Madabushi R. Clinical pharmacology basis of deriving dosing recommendations for dabigatran in patients with severe renal impairment. J Clin Pharmcol. 2012; 52(Suppl 1): 119S-125S.

81. Stangier J., Rathgen K., Stahle H., Mazur D. Influence of renal impairment on the pharmacokinetics and pharmacodynamics of oral dabigatran etexilate: an open-label, parallel-group, single-centre study. Clin Pharmacokinet. 2010; 49(4): 259-68.


Для цитирования:


Кобалава Ж.Д., Шаваров А.А. АНТИКОАГУЛЯНТНАЯ ТЕРАПИЯ ПРИ ХРОНИЧЕСКОЙ БОЛЕЗНИ ПОЧЕК И ФИБРИЛЛЯЦИИ ПРЕДСЕРДИЙ: ОСЬ ВРАЩЕНИЯ МЕЖДУ ПОЛЮСАМИ РИСКА. Евразийский кардиологический журнал. 2018;(2):64-83.

For citation:


Kobalava Z.D., Shavarov A.A. ANTICOAGULANT THERAPY FOR CHRONIC KIDNEY DISEASE AND ATRIAL FIBRILLATION: THE AXIS OF ROTATION BETWEEN THE POLES OF RISK. Eurasian heart journal. 2018;(2):64-83.

Просмотров: 17


Creative Commons License
Контент доступен под лицензией BY NC ND.


ISSN 2225-1685 (Print)
ISSN 2305-0748 (Online)